Learn more about Genomic Health's diagnostic tests, for breast and colon cancer, which can help patients and their doctors make better, more informed treament decisions.
Oncotype DX breast cancer test validated to predict local recurrence in patients with ductal carcinoma in situ DCIS, or pre-invasive breast cancer. Read more...
See how we are turning the promise of genomics into the practice of medicine. Includes a step-by-step "demo" of the Oncotype DX test process.
View a recent Bloomberg interview with CEO Kim Popovits and learn more about Genomic Health's perspective on genomics in cancer and current business highlights.
Genomic Health to Announce Fourth Quarter and Year-End 2011 Financial Results and Host Conference Call on Monday, February 6, 2012
Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
